CORO2B Antibody

What is CORO2B and what cellular functions does it regulate?

CORO2B (Coronin 2B) is a WD40-domain containing protein that functions as an actin-binding protein highly enriched in specific cell types, particularly podocytes in the kidney and neurons in the developing brain . It plays critical roles in:

• Cytoskeletal organization and actin dynamics

• Cellular adhesion and morphology

• Neuronal migration and polarity

• Podocyte foot process structure maintenance

This protein is located at the cytoplasmic side of the apical plasma membrane in podocytes and is involved in pathways essential for maintaining cellular architecture and transmitting signals that direct cell positioning .

What are the standard applications for CORO2B antibodies in research?

CORO2B antibodies are primarily used in the following experimental applications:

These applications enable researchers to investigate CORO2B expression patterns, subcellular localization, and potential roles in disease models .

In which tissues and experimental models is CORO2B antibody most effectively used?

CORO2B antibody has been successfully validated in:

• Tissue types: Brain tissue (particularly neurons), kidney glomeruli (specifically podocytes), and ovarian tissue

• Cell lines: Jurkat cells, MCF-7 cells, H441 xenografts

• Model organisms: Human, mouse, and rat samples show consistent reactivity

• Disease models: Particularly useful in diabetic nephropathy models and neuronal migration studies

When designing experiments, researchers should note that CORO2B is highly enriched in specific cell populations, which may affect detection thresholds in heterogeneous samples .

How can CORO2B antibodies be optimized for studying podocyte pathophysiology in diabetic nephropathy?

For studying CORO2B in diabetic nephropathy contexts, several optimizations are recommended:

• Sample preparation: Use fresh-frozen kidney sections rather than paraffin-embedded when possible, as CORO2B expression is significantly downregulated in diabetic nephropathy patients

• Co-localization studies: Pair CORO2B antibody (1:500) with podocyte markers like nephrin or podocin to specifically assess changes in podocyte expression

• Quantification approach:

  • Use densitometric analysis normalized to housekeeping proteins for Western blots

  • For immunohistochemistry, measure mean fluorescence intensity specifically in glomerular regions

  • Compare at least 20-30 glomeruli per sample for statistical validity

• Controls and validation: Include both diabetic and non-diabetic samples, as CORO2B shows differential expression between these conditions

Researchers should note that while CORO2B knockout mice do not show spontaneous proteinuria, they exhibit altered responses to certain pathological stimuli like protamine sulfate perfusion, suggesting context-dependent roles in podocyte pathophysiology .

What technical challenges might arise when using CORO2B antibodies in neuronal migration studies?

Researchers investigating neuronal migration using CORO2B antibodies should anticipate several technical challenges:

• Temporal expression dynamics: CORO2B expression changes during neuronal development, requiring careful timing of experiments

• Distinguishing isoforms: Multiple CORO2B isoforms may exist; ensure your antibody targets the relevant sequences

• Background in brain tissue: High background signal can occur in neural tissue; optimize blocking (recommend 4% goat serum, 1% BSA, 0.4% Triton X-100 in PBS for 20 minutes)

• Co-staining limitations: When co-staining with neuronal markers like Cux1 or Ctip2, certain antibody combinations may show cross-reactivity; perform single-staining controls

• Live imaging considerations: For dynamic studies of actin reorganization, consider complementing fixed tissue antibody labeling with lifeact-GFP or lifeact-mCherry constructs to visualize actin dynamics in live neurons

In multipolar-bipolar transition studies, researchers should combine CORO2B immunolabeling with morphological analysis since CORO2B-deficient neurons often fail to properly transition between these states .

How can apparent contradictions in CORO2B function between knockout models be reconciled methodologically?

The literature shows potentially contradictory findings regarding CORO2B function between different models:

• Tissue-specific effects: Studies indicate CORO2B knockout does not affect maintenance of the glomerular filtration barrier , yet it significantly impacts neuronal migration . To reconcile these differences:

  • Design experiments with tissue-specific knockouts rather than global knockouts

  • Use Cre-lox systems targeting either podocyte-specific (e.g., NPHS2-Cre) or neuron-specific (e.g., Nex-Cre) populations

• Context-dependent activation: CORO2B knockout podocytes show partial protection from protamine sulfate-induced foot process effacement , suggesting:

  • Include multiple stress stimuli in experimental design (e.g., streptozotocin-induced diabetes vs. protamine sulfate challenge)

  • Measure multiple endpoints beyond morphological changes (gene expression, protein interaction networks)

• Quantification methods standardization:

  • For podocyte studies: Standardize foot process effacement measurements using transmission electron microscopy with consistent magnification and sampling

  • For neuronal studies: Define precise parameters for assessing multipolar-bipolar transition using consistent morphological criteria

  • Apply automated image analysis to reduce investigator bias

• Molecular pathway analysis: Employ phosphoproteomics or proximity labeling approaches to identify differential activation of downstream pathways (particularly Rac1-dependent signaling) that may explain context-dependent functions .

What controls are essential when validating a CORO2B antibody for a new application?

For rigorous validation of CORO2B antibodies in new applications, the following controls are essential:

• Positive controls:

  • Tissue-based: Mouse brain tissue and Jurkat cells have confirmed expression

  • Recombinant protein: Use purified CORO2B recombinant protein with known concentration

• Negative controls:

  • CORO2B knockout samples where available

  • Secondary antibody-only controls to assess non-specific binding

  • Isotype controls matched to the CORO2B antibody host species

• Specificity validation:

  • Peptide competition assay: Pre-incubate antibody with the immunizing peptide

  • RNA interference: Compare staining in cells with confirmed CORO2B knockdown

  • Multiple antibody validation: Test at least two CORO2B antibodies targeting different epitopes (N-terminal vs. C-terminal regions)

• Cross-reactivity assessment:

  • Test the antibody against related coronin family proteins (CORO1A, CORO1B, CORO1C, CORO2A, CORO7)

  • Include both human and rodent samples to confirm cross-species reactivity claims

Researchers should document all validation steps according to best practices for antibody validation in the field.

How should Western blot protocols be optimized specifically for CORO2B detection?

For optimal Western blot detection of CORO2B, researchers should follow these specific recommendations:

• Sample preparation:

  • For tissue samples: Homogenize in RIPA buffer supplemented with protease inhibitors

  • For cellular samples: Direct lysis in 2X Laemmli buffer often yields better results

  • Include phosphatase inhibitors if studying phosphorylation states

• Gel and transfer parameters:

  • Use 10% SDS-PAGE gels for optimal resolution around 54 kDa (CORO2B's observed MW)

  • Transfer to PVDF membranes (rather than nitrocellulose) for enhanced protein retention

  • Transfer at 100V for 60 minutes in cold transfer buffer containing 20% methanol

• Blocking and antibody incubation:

  • Block with 5% non-fat dry milk in TBST (most effective for reducing background)

  • Dilute primary CORO2B antibody to 1:1000 in 5% BSA in TBST

  • Incubate overnight at 4°C with gentle agitation

  • Use HRP-conjugated secondary antibodies at 1:5000 dilution

• Detection system optimization:

  • Enhanced chemiluminescence (ECL) detection systems are sufficient

  • Exposure times typically range from 30 seconds to 5 minutes

  • Expected band size is approximately 54 kDa

When troubleshooting, note that high background may occur with certain tissue types; in these cases, increase washing steps (5x 5-minute washes) and consider using alternative blocking agents like fish gelatin.

What methodological approaches best reveal CORO2B's role in cytoskeletal dynamics?

To effectively study CORO2B's role in cytoskeletal dynamics, researchers should consider these methodological approaches:

• Live-cell imaging techniques:

  • Co-express CORO2B-GFP fusion proteins with lifeact-mCherry to visualize actin dynamics

  • Use TIRF microscopy for high-resolution imaging of cortical actin structures

  • Employ FRAP (Fluorescence Recovery After Photobleaching) to measure CORO2B turnover rates at actin structures

• Protein-protein interaction studies:

  • Co-immunoprecipitation of CORO2B to identify binding partners (particularly CFL1)

  • Proximity ligation assays to visualize and quantify CORO2B interactions with actin regulatory proteins in situ

  • Use FRET-based biosensors to measure CORO2B-dependent Rac1 activation in real-time

• Functional perturbation approaches:

  • Compare actin dynamics in control vs. CORO2B knockdown cells using F-actin/G-actin fractionation

  • Employ the PBD-EYFP construct to measure Rac1 activity levels as CORO2B modulates cytoskeletal dynamics through Rac1-dependent pathways

  • Use established actin polymerization/depolymerization assays with purified components

• Structural analysis:

  • Employ super-resolution microscopy (STED, STORM) to visualize CORO2B localization relative to actin structures at nanoscale resolution

  • Correlative light and electron microscopy to link CORO2B localization with ultrastructural features

These approaches can be particularly powerful when combined in a single study to provide multiple lines of evidence for CORO2B's cytoskeletal functions .

How can researchers address inconsistent CORO2B staining patterns in immunohistochemistry?

Inconsistent CORO2B staining in immunohistochemistry can be addressed through several targeted approaches:

• Fixation optimization:

  • Test multiple fixation protocols: 4% PFA (12-24 hours) works well for most neural tissues

  • For kidney tissues, shorter fixation times (4-6 hours) may better preserve epitopes

  • Consider alternative fixatives like methanol for certain applications

• Antigen retrieval comparison:

  • For FFPE sections: Compare citrate buffer (pH 6.0) versus TE buffer (pH 9.0)

  • For kidney tissues: TE buffer (pH 9.0) often yields superior results

  • Test multiple retrieval durations (10-30 minutes)

• Antibody selection and validation:

  • Test antibodies targeting different epitopes (N-terminal vs. C-terminal)

  • Validate using tissue with confirmed CORO2B expression (brain, kidney)

  • Consider lot-to-lot variability with polyclonal antibodies

• Signal amplification strategies:

  • For low-abundance expression: Implement tyramide signal amplification

  • Biotin-streptavidin systems can enhance detection sensitivity

  • Consider automated IHC platforms for consistent staining

For tissue-specific optimization, note that kidney tissues often require more stringent antigen retrieval conditions, while brain tissues may benefit from longer primary antibody incubation times (up to 48 hours at 4°C) at higher dilutions (1:500-1:1000) .

What approaches can reconcile contradictory findings about CORO2B expression patterns in different studies?

To address contradictory findings regarding CORO2B expression patterns, researchers should implement these methodological approaches:

• Comprehensive expression profiling:

  • Combine multiple detection methods: qRT-PCR, Western blot, immunohistochemistry

  • Analyze expression across developmental stages (embryonic to adult)

  • Map expression in multiple tissues systematically

• Single-cell resolution approaches:

  • Employ single-cell RNA-seq to identify cell populations with CORO2B expression

  • Use RNAscope or similar in situ hybridization techniques to validate transcript localization

  • Combine with immunofluorescence for protein-level confirmation

• Antibody benchmarking:

  • Compare multiple commercial antibodies side-by-side using identical samples

  • Document specific clone/lot numbers in publications

  • Create standardized positive controls (e.g., CORO2B-overexpressing cell lines)

• Data integration and meta-analysis:

  • Systematically compare methodologies across contradictory studies

  • Account for species differences (human vs. mouse vs. rat)

  • Consider disease state impacts (normal vs. pathological conditions)

This multi-faceted approach can help determine whether contradictions arise from methodological differences, biological variability, or actual context-dependent expression patterns of CORO2B .

How can researchers experimentally determine if CORO2B phosphorylation affects antibody recognition?

Post-translational modifications like phosphorylation can affect antibody recognition. To determine if this applies to CORO2B detection:

• Phosphorylation state manipulation:

  • Compare antibody detection in samples treated with/without phosphatase inhibitors

  • Pre-treat lysates with lambda phosphatase before Western blotting

  • Generate or obtain phospho-mimetic (S/T→D) and phospho-dead (S/T→A) CORO2B mutants

• Epitope-specific analysis:

  • Map the epitope recognized by the antibody using epitope prediction tools

  • Determine if predicted epitopes contain known/potential phosphorylation sites

  • Compare antibodies targeting different regions of CORO2B

• Phosphorylation-specific detection methods:

  • Use Phos-tag™ SDS-PAGE to separate phosphorylated from non-phosphorylated forms

  • Perform 2D gel electrophoresis to resolve charge variants

  • Consider phospho-specific antibody development if key sites are identified

• Mass spectrometry validation:

  • Perform immunoprecipitation followed by mass spectrometry

  • Identify phosphorylation sites present in CORO2B under various conditions

  • Correlate phosphorylation status with antibody detection efficiency

This systematic approach can determine whether CORO2B phosphorylation affects antibody recognition and may reveal functional insights about CORO2B regulation .

How can CORO2B antibodies be employed in studying the molecular mechanisms of neuronal polarization?

For investigating CORO2B's role in neuronal polarization, researchers should consider these advanced methodological approaches:

• Temporal analysis of CORO2B localization:

  • Use time-lapse imaging with CORO2B antibody staining at defined developmental stages

  • Correlate CORO2B distribution with stages of neuronal polarization (multipolar to bipolar transition)

  • Implement stage-specific knockdown using inducible shRNA systems

• Subcellular compartment-specific analysis:

  • Perform subcellular fractionation followed by Western blotting with CORO2B antibodies

  • Use super-resolution microscopy to map CORO2B distribution relative to polarity markers

  • Employ proximity labeling approaches (BioID, APEX) to identify compartment-specific CORO2B interactors

• Rac1 pathway integration:

  • Visualize Rac1 activity using FRET-based biosensors in CORO2B-deficient neurons

  • Perform rescue experiments with constitutively active (Rac1-G12V) or dominant negative (Rac1-T17N) constructs

  • Map spatiotemporal correlation between CORO2B localization and Rac1 activity zones during polarization

• Cytoskeletal dynamics assessment:

  • Combine CORO2B immunolabeling with quantitative analysis of F-actin distribution

  • Track formation of leading processes using live-cell imaging in control vs. CORO2B-deficient neurons

  • Assess cofilin phosphorylation state (cofilin-S3) as a downstream effector of CORO2B function

These approaches provide mechanistic insight into how CORO2B orchestrates cytoskeletal reorganization during the critical multipolar-bipolar transition in neuronal development .

What methodological considerations are important when studying CORO2B in the context of disease models?

When investigating CORO2B in disease contexts, researchers should implement these methodological considerations:

• For diabetic nephropathy studies:

  • Compare CORO2B expression across disease progression (early vs. advanced nephropathy)

  • Correlate CORO2B levels with clinical parameters (proteinuria, GFR)

  • Use multiple diabetes models (streptozotocin-induced, genetic models like db/db mice)

• For neurological disorder investigations:

  • Assess CORO2B expression in models of neuronal migration disorders

  • Correlate CORO2B dysfunction with seizure susceptibility using standardized protocols

  • Include both acute and chronic disease models to distinguish primary vs. adaptive changes

• Experimental design considerations:

  • Include appropriate age and sex-matched controls

  • Design time-course studies to capture disease progression

  • Consider genetic background effects in knockout models

• Translational approaches:

  • Validate findings in human patient samples when available

  • Implement tissue microarrays for higher-throughput analysis

  • Consider therapeutic targeting strategies (e.g., small molecule modulation of CORO2B-dependent pathways)

For quantitative assessment, researchers should establish standardized scoring systems specific to each disease model, with blinded evaluation to minimize investigator bias .

How can researchers effectively combine CORO2B antibodies with other molecular tools to elucidate its role in focal adhesion dynamics?

To comprehensively investigate CORO2B's function in focal adhesion dynamics, researchers should implement this integrated methodological approach:

• Multi-protein co-localization analysis:

  • Perform triple immunofluorescence with CORO2B antibody and focal adhesion markers (paxillin, vinculin)

  • Use proximity ligation assays to visualize and quantify CORO2B interactions with focal adhesion proteins

  • Implement structured illumination microscopy for enhanced spatial resolution of protein complexes

• Live-cell focal adhesion dynamics:

  • Combine CORO2B-fluorescent protein fusions with established focal adhesion markers

  • Employ FRAP or photoactivation to measure CORO2B turnover at adhesion sites

  • Implement traction force microscopy to correlate CORO2B localization with mechanical force generation

• Proteomic approaches:

  • Perform quantitative focal adhesome proteomics in control vs. CORO2B-deficient cells

  • Use BioID or APEX2 proximity labeling with CORO2B as bait to identify adhesion-specific interactors

  • Implement crosslinking mass spectrometry to map interaction interfaces

• Functional perturbation strategies:

  • Create domain-specific CORO2B mutants to dissect functional regions

  • Perform acute perturbation using optogenetic approaches to manipulate CORO2B localization

  • Study CFL1 recruitment to focal adhesions in CORO2B-deficient backgrounds

This comprehensive approach leverages the finding that CORO2B serves as a physical linkage module to cell-matrix adhesion sites and influences the recruitment of CFL1 to focal adhesions .